0.5017
3.48%
-0.0182
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News
Citius Pharmaceuticals defers FDA milestone payment - Investing.com
Citius Pharmaceuticals defers FDA milestone payment By Investing.com - Investing.com UK
Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Financial Metrics Check: Citius Pharmaceuticals Inc (CTXR)’s Ratios for Trailing Twelve Months - The Dwinnex
Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com
Citius Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com Canada
There is no way Citius Pharmaceuticals Inc (CTXR) can keep these numbers up - SETE News
Insider’s View: Deciphering Citius Pharmaceuticals Inc (CTXR)’s Financial Health Through Ratios - The Dwinnex
Can you still get a good price for Citius Pharmaceuticals Inc (CTXR) Shares at this point? - US Post News
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - The Malaysian Reserve
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Malaysian Reserve
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - PR Newswire
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
You might want to take a look at Citius Pharmaceuticals Inc (CTXR) now - SETE News
Market Momentum Report: Citius Pharmaceuticals Inc (CTXR)’s Positive Close at 0.57 - The Dwinnex
Citius Pharmaceuticals Inc (CTXR) requires closer examination - US Post News
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Drop in Short Interest - MarketBeat
Arkadios Wealth Advisors Has $88,000 Holdings in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com India
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com Canada
In the Green: Citius Pharmaceuticals Inc (CTXR) Closes at 0.59, Up/Down -12.96 from Previous Day - The Dwinnex
It makes sense and dollars to buy Citius Pharmaceuticals Inc (CTXR) stock - SETE News
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com UK
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Are Citius Pharmaceuticals Inc (CTXR) shares a good deal now? - US Post News
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks
CTXRW (Citius Pharmaceuticals) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia
Vanguard Group Inc. Has $6.29 Million Stake in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Oncology Inc. completes strategic acquisition - Investing.com
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Canada
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com UK
CTXRW (Citius Pharmaceuticals) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com
Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ
Citius Pharmaceuticals (NASDAQ:CTXR) Releases Quarterly Earnings Results - MarketBeat
Citius merges oncology subsidiary with TenX Keane - Yahoo Finance
Citius merges oncology subsidiary with TenX Keane - Pharmaceutical Technology
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - The Malaysian Reserve
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - StockTitan
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024 - Marketscreener.com
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - StockTitan
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - BioSpace
Citius Pharmaceuticals Inc Inc. (CTXR) Price Performance: The Role of Supply and Demand - The InvestChronicle
Trading Day Review: Citius Pharmaceuticals Inc (CTXR) Loses Momentum, Closing at 0.78 - The Dwinnex
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Nasdaq
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year - AOL
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com
TenX Keane Acquisition Addresses Trading Halt, Continues - GlobeNewswire
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - StockTitan
FDA Greenlights Citius' Blood Cancer Therapy After Initial Rejection - Finimize
Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection - Benzinga
New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online
US FDA approves Citius' therapy for rare blood cancer - Reuters.com
Citius wins FDA nod for lead drug Lymphir (NASDAQ:CTXR) - Seeking Alpha
FDA clears Citius’ IL-2 therapy Lymphyr for CTCL - BioWorld Online
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):